<p>/PRNewswire/ -- Aethlon Medical, Inc.（“Aethlon” 或 “公司”）（納斯達克：AEMD）是一家專注於開發治療癌症和危及生命的傳染病產品的醫療治療公司，今天宣佈已與單一機構投資者簽署了一項證券購買協議，購買 595,897 股普通股（或預先融資的認股權證），以及可購買最多 1,042,820 股普通股的認股權證，進行一項根據納斯達克規則按市場價格定價的私募。每股普通股（或預先融資的認股權證）及其附帶認股權證的綜合有效發行價格為 4.03 美元。認股權證的行使價格為每股 4.03 美元，需經股東批准後方可行使，並將在股東批准之日起五年半後到期。</p>
<p>公司還與投資者簽署了一項認股權證誘導協議，以行使公司在 2025 年 3 月（“2025 年 3 月認股權證”）和 2025 年 9 月（“2025 年 9 月認股權證”）分別發行的某些未行使認股權證。根據認股權證誘導協議，投資者同意將未行使的 2025 年 3 月認股權證和 2025 年 9 月認股權證的行使價格降低至修訂後的 4.03 美元，並行使未行使的 2025 年 3 月認股權證購買公司普通股的總計 155,000 股，以及未行使的 2025 年 9 月認股權證購買公司普通股的總計 55,555 股，行使價格為修訂後的 4.03 美元。作為對立即行使 2025 年 3 月認股權證和 2025 年 9 月認股權證的對價，公司還同意向投資者發行未註冊的認股權證，以購買公司普通股的總計 368,471 股（“新認股權證”）。新認股權證的行使價格為每股 4.03 美元，需經股東批准後方可行使，並將在股東批准之日起五年半後到期。</p>
<p>公司從私募和認股權證誘導中獲得的總收入預計約為 330 萬美元，未扣除承銷商費用和其他預計的發行費用。該發行預計將在 2025 年 12 月 8 日左右完成，前提是滿足慣例的交割條件。</p>
<p>Maxim Group LLC 作為此次發行的唯一承銷商。</p>
<p>上述證券的發行和銷售是在 1933 年證券法（“證券法”）第 4(a)(2) 條及其下頒佈的 D 條款的私募中進行的，且這些證券未在證券法或適用的州證券法下注冊。因此，除非根據有效的註冊聲明或適用的證券法註冊要求的豁免，否則這些證券不得在美國轉售或再提供。公司已同意向證券交易委員會提交註冊聲明，以註冊在私募和認股權證誘導中發行的證券的轉售。</p>
<p>本新聞稿不構成出售證券的要約或購買證券的邀請，也不應在任何州進行證券的銷售，除非在該州的證券法下注冊或資格之前，該要約、邀請或銷售是非法的。根據轉售註冊聲明的任何證券發行僅通過招股説明書進行。</p>
<p><strong>關於 Aethlon Medical, Inc.</strong></p>
<p>Aethlon Medical, Inc.（納斯達克：AEMD）是一家總部位於加利福尼亞州聖地亞哥的臨牀階段醫療設備公司。Aethlon 正在推進 Hemopurifier，以滿足腫瘤學和傳染病領域的未滿足需求，使用一種新穎的平台，旨在選擇性去除生物液體中的循環病原體目標。</p>
<p>欲瞭解更多信息，請訪問 www.AethlonMedical.com 並在 LinkedIn 上關注公司。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條的定義的前瞻性聲明，這些聲明涉及風險和不確定性。包含 “可能”、“相信”、“預期”、“期待”、“打算”、“計劃”、“項目”、“將”、“預測”、“估計”、“潛在” 或類似表達的聲明構成前瞻性聲明。這些前瞻性聲明受到重大風險和不確定性的影響，實際結果可能與前瞻性聲明中預期的結果有重大差異。這些前瞻性聲明基於 Aethlon 當前的預期，並涉及可能永遠無法實現或可能被證明不正確的假設。可能導致這些差異的因素包括但不限於：公司籌集額外資本的能力、維持其納斯達克上市的能力、成功完成 Hemopurifier 的開發的能力；公司成功展示 Hemopurifier 在癌症和傳染病以及移植環境中的效用的能力；Hemopurifier 在相當於 4 小時 HP 治療的時間點繼續顯示去除血小板衍生 EVs 的能力；公司實現和實現其潛在里程碑的預期收益的能力；公司向澳大利亞和印度的額外倫理委員會提交申請並獲得批准的能力，包括公司預期的時間；公司在澳大利亞和印度啓動和繼續其計劃中的腫瘤臨牀試驗的能力，包括公司預期的時間；公司管理和成功完成其臨牀試驗（如果啓動）的能力；公司成功製造足夠數量的 Hemopurifier 以供其臨牀試驗的能力，以及其他潛在風險。上述風險和不確定性清單僅為示例，並非詳盡無遺。可能導致結果與前瞻性聲明中預期的結果有重大差異的其他因素可以在公司截至 2025 年 3 月 31 日的 10-K 表格年度報告中的 “風險因素” 標題下找到，以及公司向證券交易委員會提交的其他文件，包括其 10-Q 表格的季度報告。本新聞稿中包含的所有前瞻性聲明僅在作出聲明的日期有效。除非法律要求，否則公司不打算也不承擔任何更新此信息以反映未來事件或情況的義務。</p>
<p><strong>公司聯繫人：</strong> Jim Frakes</p>
<p>首席執行官兼首席財務官</p>
<p>Aethlon Medical, Inc.</p>
<p>Jfrakes@aethlonmedical.com</p>
<p><strong>投資者聯繫人：</strong> Susan Noonan</p>
<p>S.A. Noonan Communications, LLC</p>
<p>susan@sanoonan.com</p>
<p>917-513-5303</p>
<p>來源：Aethlon Medical, Inc.</p>

AEMD

<p>Aethlon Medical, Inc. 宣佈與一位機構投資者達成了一項 330 萬美元的私募協議，涉及普通股和認股權證的購買。該發行價格符合納斯達克規則的市場價格，認股權證需經股東批准後方可行使。公司還簽署了一項認股權證誘導協議，以修改現有認股權證的行使價格。該發行預計將在 2025 年 12 月 8 日之前完成，Maxim Group LLC 擔任配售代理。該證券以私募方式發行，未在證券法下注冊</p>

<p>, /PRNewswire/ -- Aethlon Medical, Inc. (&#34;Aethlon&#34; or the &#34;Company&#34;) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants is $4.03. The warrants will have an exercise price of $4.03 per share, will be exercisable upon shareholder approval, and will expire on the five and one-half year anniversary from such date of shareholder approval.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Aethlon Medical, Inc.（“Aethlon” 或 “公司”）（納斯達克：AEMD）是一家專注於開發治療癌症和危及生命的傳染病產品的醫療治療公司，今天宣佈已與單一機構投資者簽署了一項證券購買協議，購買 595,897 股普通股（或預先融資的認股權證），以及可購買最多 1,042,820 股普通股的認股權證，進行一項根據納斯達克規則按市場價格定價的私募。每股普通股（或預先融資的認股權證）及其附帶認股權證的綜合有效發行價格為 4.03 美元。認股權證的行使價格為每股 4.03 美元，需經股東批准後方可行使，並將在股東批准之日起五年半後到期。</p>
</div><p>The Company has also entered into a warrant inducement agreement with the investor to exercise certain outstanding warrants that the Company issued in March 2025 (the &#34;March 2025 Warrants&#34;) and September 2025 (the &#34;September 2025 Warrants&#34;), respectively. Pursuant to a warrant inducement agreement, the investor has agreed to a reduced exercise price of the outstanding March 2025 Warrants and September 2025 Warrants to an amended exercise price of $4.03, and to exercise the outstanding March 2025 Warrants to purchase an aggregate of 155,000 shares of the Company's common stock and the outstanding September 2025 Warrants to purchase an aggregate of 55,555 shares of the Company's common stock, at the amended exercise price of $4.03. In consideration for the immediate exercise of the March 2025 Warrants and September 2025 Warrants, the Company also agreed to issue the investor unregistered warrants to purchase an aggregate of 368,471 shares of the Company's common stock (the &#34;New Warrants&#34;). The New Warrants will have an exercise price of $4.03 per share, will be exercisable upon shareholder approval, and will expire on the five and one-half year anniversary from such date of shareholder approval.</p>
<div class="lb-trans"><p>公司還與投資者簽署了一項認股權證誘導協議，以行使公司在 2025 年 3 月（“2025 年 3 月認股權證”）和 2025 年 9 月（“2025 年 9 月認股權證”）分別發行的某些未行使認股權證。根據認股權證誘導協議，投資者同意將未行使的 2025 年 3 月認股權證和 2025 年 9 月認股權證的行使價格降低至修訂後的 4.03 美元，並行使未行使的 2025 年 3 月認股權證購買公司普通股的總計 155,000 股，以及未行使的 2025 年 9 月認股權證購買公司普通股的總計 55,555 股，行使價格為修訂後的 4.03 美元。作為對立即行使 2025 年 3 月認股權證和 2025 年 9 月認股權證的對價，公司還同意向投資者發行未註冊的認股權證，以購買公司普通股的總計 368,471 股（“新認股權證”）。新認股權證的行使價格為每股 4.03 美元，需經股東批准後方可行使，並將在股東批准之日起五年半後到期。</p>
</div><p>The gross proceeds to the Company from the private placement and warrant inducement are estimated to be approximately $3.3 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 8, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>公司從私募和認股權證誘導中獲得的總收入預計約為 330 萬美元，未扣除承銷商費用和其他預計的發行費用。該發行預計將在 2025 年 12 月 8 日左右完成，前提是滿足慣例的交割條件。</p>
</div><p>Maxim Group LLC is acting as the sole placement agent in connection with the offering.</p>
<div class="lb-trans"><p>Maxim Group LLC 作為此次發行的唯一承銷商。</p>
</div><p>The offer and sale of the foregoing securities are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities issued in the private placement and warrant inducement.</p>
<div class="lb-trans"><p>上述證券的發行和銷售是在 1933 年證券法（“證券法”）第 4(a)(2) 條及其下頒佈的 D 條款的私募中進行的，且這些證券未在證券法或適用的州證券法下注冊。因此，除非根據有效的註冊聲明或適用的證券法註冊要求的豁免，否則這些證券不得在美國轉售或再提供。公司已同意向證券交易委員會提交註冊聲明，以註冊在私募和認股權證誘導中發行的證券的轉售。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.</p>
<div class="lb-trans"><p>本新聞稿不構成出售證券的要約或購買證券的邀請，也不應在任何州進行證券的銷售，除非在該州的證券法下注冊或資格之前，該要約、邀請或銷售是非法的。根據轉售註冊聲明的任何證券發行僅通過招股説明書進行。</p>
</div><p><strong>About Aethlon Medical, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Aethlon Medical, Inc.</strong></p>
</div><p>Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.</p>
<div class="lb-trans"><p>Aethlon Medical, Inc.（納斯達克：AEMD）是一家總部位於加利福尼亞州聖地亞哥的臨牀階段醫療設備公司。Aethlon 正在推進 Hemopurifier，以滿足腫瘤學和傳染病領域的未滿足需求，使用一種新穎的平台，旨在選擇性去除生物液體中的循環病原體目標。</p>
</div><p>For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.AethlonMedical.com 並在 LinkedIn 上關注公司。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as &#34;may,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;project,&#34; &#34;will,&#34; &#34;projections,&#34; &#34;estimate,&#34; &#34;potentially&#34; or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital, its ability to maintain its Nasdaq listing, to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the ability of the Hemopurifier to continue to show removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment; the Company's ability to achieve and realize the anticipated benefits from its potential milestones; the Company's ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company's ability to initiate and continue its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company's ability to manage and successfully complete its clinical trials, if initiated; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption &#34;Risk Factors&#34; in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條的定義的前瞻性聲明，這些聲明涉及風險和不確定性。包含 “可能”、“相信”、“預期”、“期待”、“打算”、“計劃”、“項目”、“將”、“預測”、“估計”、“潛在” 或類似表達的聲明構成前瞻性聲明。這些前瞻性聲明受到重大風險和不確定性的影響，實際結果可能與前瞻性聲明中預期的結果有重大差異。這些前瞻性聲明基於 Aethlon 當前的預期，並涉及可能永遠無法實現或可能被證明不正確的假設。可能導致這些差異的因素包括但不限於：公司籌集額外資本的能力、維持其納斯達克上市的能力、成功完成 Hemopurifier 的開發的能力；公司成功展示 Hemopurifier 在癌症和傳染病以及移植環境中的效用的能力；Hemopurifier 在相當於 4 小時 HP 治療的時間點繼續顯示去除血小板衍生 EVs 的能力；公司實現和實現其潛在里程碑的預期收益的能力；公司向澳大利亞和印度的額外倫理委員會提交申請並獲得批准的能力，包括公司預期的時間；公司在澳大利亞和印度啓動和繼續其計劃中的腫瘤臨牀試驗的能力，包括公司預期的時間；公司管理和成功完成其臨牀試驗（如果啓動）的能力；公司成功製造足夠數量的 Hemopurifier 以供其臨牀試驗的能力，以及其他潛在風險。上述風險和不確定性清單僅為示例，並非詳盡無遺。可能導致結果與前瞻性聲明中預期的結果有重大差異的其他因素可以在公司截至 2025 年 3 月 31 日的 10-K 表格年度報告中的 “風險因素” 標題下找到，以及公司向證券交易委員會提交的其他文件，包括其 10-Q 表格的季度報告。本新聞稿中包含的所有前瞻性聲明僅在作出聲明的日期有效。除非法律要求，否則公司不打算也不承擔任何更新此信息以反映未來事件或情況的義務。</p>
</div><p><strong>Company Contacts:</strong> Jim Frakes</p>
<div class="lb-trans"><p><strong>公司聯繫人：</strong> Jim Frakes</p>
</div><p>Chief Executive Officer and Chief Financial Officer</p>
<div class="lb-trans"><p>首席執行官兼首席財務官</p>
</div><p>Aethlon Medical, Inc.</p>
<div class="lb-trans"><p>Aethlon Medical, Inc.</p>
</div><p>Jfrakes@aethlonmedical.com</p>
<div class="lb-trans"><p>Jfrakes@aethlonmedical.com</p>
</div><p><strong>Investor Contact:</strong> Susan Noonan</p>
<div class="lb-trans"><p><strong>投資者聯繫人：</strong> Susan Noonan</p>
</div><p>S.A. Noonan Communications, LLC</p>
<div class="lb-trans"><p>S.A. Noonan Communications, LLC</p>
</div><p>susan@sanoonan.com</p>
<div class="lb-trans"><p>susan@sanoonan.com</p>
</div><p>917-513-5303</p>
<div class="lb-trans"><p>917-513-5303</p>
</div><p>SOURCE Aethlon Medical, Inc.</p>
<div class="lb-trans"><p>來源：Aethlon Medical, Inc.</p>
</div>

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million | AEMD Stock News

Aethlon Medical 宣佈以市場價格定價進行私人配售和認股權證激勵，總募集資金為 330 萬美元 | AEMD 股票新聞